AUA Summit - Bladder Cancer

advertisement

Bladder Cancer

Courses

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genentech, Genomic Health, Merck, Pfizer, Inc. and Sanofi Genzyme.

023IC – Chemotherapy and Immunotherapy Options for Genitourinary Malignancies: A Primer for Urologists and Advanced Practice Providers

Claim CME   Play   

023IC - Chemotherapy and Immunotherapy Options for Genitourinary Malignancies: A Primer for Urologists and Advanced Practice Providers

Support provided by independent educational grants from AstraZeneca, Bristol-Myers Squibb, Genentech and Merck.

072IC – Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems

Claim CME   Play   

072IC - Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genentech, Genomic Health, Merck, Pfizer, Inc. and Sanofi Genzyme.

077IC – Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics

Claim CME   Play   

077IC - Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics

Live from AUA

This educational activity is supported by independent educational grants from Astellas, Merck, and Seattle Genetics.

Management of Non-Muscle Invasive Urothelial Carcinoma

Claim CME   Play   

Management of Non-Muscle Invasive Urothelial Carcinoma

Management of Advanced and Metastatic Urothelial Carcinoma

Claim CME   Play   

Management of Advanced and Metastatic Urothelial Carcinoma